EUVIMEDEUVIMED entdecken
Open Access

Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma

Gilbert Youssef iD, Elisa Aquilanti iD, Julie J Miller, Zhou Lan, Aleksandra B Lasica iD, Isabel Arrillaga-Romany iD, Tracy T Batchelor, Tamar R Berger, Rameen Beroukhim, Ugonma Chukwueke iD, Jorg Dietrich iD, Deborah A Forst und 13 weitere

Neuro-Oncology · 01.03.2026 · 28 (3) · 752-764

DOI: 10.1093/neuonc/noaf287 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 15.12.2025. Verfasst von Gilbert Youssef und 24 weiteren Autor:innen. Beteiligte Einrichtung: Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston. Hauptthemen laut MEDLINE: Glioma, DNA Methylation, Isocitrate Dehydrogenase, Promoter Regions, Genetic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH, NINDS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AbstractAbstract Background The prognostic and predictive value of O6-methylguanine-DNA methyltransferase promoter (MGMTp) methylation is not well established in isocitrate dehydrogenase (IDH)-mutant gliomas. This study evaluates the survival impact of MGMTp and other clinical, molecular, and radiologic variables in low-grade and high-grade IDH-mutant gliomas.

Methods

We retrospectively evaluated 520 consecutive adult patients treated for an initial diagnosis of IDH-mutant glioma, of any histological grade, at two large academic institutions. MGMTp methylation was evaluated by methylation-specific polymerase chain reaction (PCR) analysis. Log-rank test and Cox proportional hazards model were applied to evaluate the association of clinical, molecular, and radiological characteristics with overall survival (OS) and progression-free survival (PFS).

Results

Median age was 36.6 years; MGMTp was methylated in 70% and unmethylated in 30%. MGMTp methylation was not significantly associated with OS (P = 0.11) or PFS (P = 0.74) on multivariate analyses. Cyclin dependent kinase inhibitor 2A/B (CDKN2A/B) homozygous deletion [HR = 3.26 (1.47, 7.23), P = .006] and an integrated grade 4 classification [HR = 2.08 (1.06, 4.67), P = .048] were strong predictors of OS in astrocytoma, whereas maximal resection [HR = 0.06 (0.01, 0.57), p = 0.016] and radiation [HR = 0.41 (0.18, 0.91), P = .03] were strong prognosticators for PFS in the entire cohort. Maximal resection of the enhancing disease [HR = 0.17 (0.05, 0.96), P = .014] and radiation [HR = 0.47 (0.19, 0.65), P = .046] were strongly associated with PFS in grade 2 and 3 gliomas.

Conclusion

MGMTp methylation was not associated with a prognostic or predictive value in our IDH-mutant glioma cohort. CDKN2A/B status and extent of resection were strong predictors of outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaDNA MethylationIsocitrate DehydrogenasePromoter Regions, GeneticBrain NeoplasmsMutationDNA Modification MethylasesDNA Repair EnzymesTumor Suppressor ProteinsBiomarkers, TumorHumansMaleFemaleAdultPrognosisRetrospective StudiesMiddle AgedAgedYoung AdultSurvival RateFollow-Up StudiesAdolescent

Stichwörter der Autor:innen

IDH-mutant gliomaMGMT promoter methylationprognosis

Substanzen

Isocitrate DehydrogenaseDNA Modification MethylasesDNA Repair EnzymesTumor Suppressor ProteinsMGMT protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston.
  • Harvard Medical School, Harvard University, Boston.
  • Pappas Center for Neuro-Oncology, Department of Neurology, Massachusetts General Hospital, Boston.
  • Center for Clinical Investigation, Brigham and Women's Hospital, Boston.
  • Department of Neurology, Brigham and Women's Hospital, Boston.
  • Brain & Spine Tumor Center, Perlmutter Cancer Center, NYU Langone Health, New York.

ORCID-Profile: Gilbert Youssef, Elisa Aquilanti, Aleksandra B Lasica, Isabel Arrillaga-Romany, Ugonma Chukwueke, Jorg Dietrich, Lakshmi Nayak, Vihang Nakhate, Patrick Y Wen

Förderung

  • NIH
  • NINDS
  • NCI NIH HHS
  • American Cancer Society, Advisory Board
  • NIH HHS
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Youssef, G., Aquilanti, E., Miller, J. J., Lan, Z., Lasica, A. B., Arrillaga-Romany, I., Batchelor, T. T., Berger, T. R., Beroukhim, R., Chukwueke, U., Dietrich, J., Forst, D. A., Gerstner, E. R., Castro, L. N. G., Jordan, J. T., Mcfaline-Figueroa, J. R., Lee, E. Q., Nayak, L., Nakhate, V., …, & Wen, P. Y. (2026). Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma. Neuro-Oncology, 28(3), 752-764. https://doi.org/10.1093/neuonc/noaf287

Vancouver

Youssef G, Aquilanti E, Miller JJ, Lan Z, Lasica AB, Arrillaga-Romany I, et al. Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma. Neuro-Oncology. 2026;28(3):752-764. doi:10.1093/neuonc/noaf287

BibTeX
@article{Youssef2026,
  author = {Youssef, Gilbert and Aquilanti, Elisa and Miller, Julie J and Lan, Zhou and Lasica, Aleksandra B and Arrillaga-Romany, Isabel and Batchelor, Tracy T and Berger, Tamar R and Beroukhim, Rameen and Chukwueke, Ugonma and Dietrich, Jorg and Forst, Deborah A and Gerstner, Elizabeth R and Castro, L Nicolas Gonzalez and Jordan, Justin T and Mcfaline-Figueroa, J Ricardo and Lee, Eudocia Quant and Nayak, Lakshmi and Nakhate, Vihang and Ospina, Juan Pablo and Plotkin, Scott R and Wang, Nancy and Rhee, John Y and Reardon, David A and Wen, Patrick Y},
  title = {Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma},
  journal = {Neuro-Oncology},
  year = {2026},
  volume = {28},
  number = {3},
  pages = {752--764},
  doi = {10.1093/neuonc/noaf287}
}
Kostenlos starten →